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THE ROLE OF MICROBIOTA IN GASTROINTESTINAL CANCERS 
NORBERT SMIETALO 
ABSTRACT 
 The human microbiome plays an integral role in a healthy gastrointestinal (GI) 
tract. Interestingly, the GI tract is a location where microbes and their byproducts, host 
epithelium, and host immunity each interact with one another. As a result of this complex 
interplay, a signal imbalance of one may result in dysfunction. Recently, microbiota have 
been implicated in many disease states involving the GI tract, including chronic 
inflammatory states and cancer development. Their role in promoting or deterring against 
chronic inflammatory states is difficult to assess as their number within an intestinal 
population is exceedingly large, as well as the variation of microbial species found within 
human individuals. NSAIDs, antibiotics, and, more recently probiotics, have begun to 
increase in popularity for the treatment of inflammatory bowel states. Understanding the 
difference between “good” bacteria and “bad” bacteria can help research preventive and 
treatment measures for patients suffering from a microbial imbalance.  
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INTRODUCTION 
An important aspect of the digestive tract is the interaction between the 
microbiota and the host immune system. Quickly after birth, the mucosal surfaces 
exposed to air become colonized by microbes, including the gastrointestinal tract, the 
urogenital tract, skin, and lungs [1, 2]. Microbes established within the intestinal system 
are crucial to the health and stability of the tract. Normal function of gut microbes 
includes extraction of nutrients and energy from the diet, partly by catalysis of 
indigestible plant product as well as production of short chain fatty acids, contribution to 
host immune function, and protection from exogenous pathogens [2,3]. Additionally, the 
gut microbiota can alter the local pH, activate host immune cells, starve invaders by 
metabolizing available nutrients, and maintain mucosal barriers and epithelial integrity 
[3-7]. The importance of a healthy gut microbiota cannot be understated and it has been 
shown that increased microbial variation is linked with better health [8]. Dysbiosis can be 
defined as the opposite, an imbalance of the microbial population, which is correlated 
with poor health [9].  
 Dysbiosis of the gut has been shown to be associated with multiple disorders, 
including obesity, ulcerative colitis (UC), Crohn’s disease (CD), irritable bowel disease 
(IBD), and multiple cancers [10-12]. Specifically, this dysbiosis may be due to change in 
number, diversity, and stability of the microbial ecosystems [13]. These imbalances cause 
concern because chronic bowel inflammation has been shown to  
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result in elevated risk of colorectal cancer (CRC) [14]. Colorectal cancer is the 3rd most 
prevalent form of cancer worldwide. As only 20% of CRC cases are attributed to genetic 
disorders, other factors, including effects of the microbiome, are important to our 
understanding of the cause and progression of this disease [15, 16]. A specific form of 
CRC known as colitis associated cancer (CAC) has been shown to be specifically linked 
with chronic inflammatory bowel states including UC, IBD, and CD. Specifically, CAC 
risk tends to increase by 18-20% in UC patients and 10% in CD [17, 18]. The exact 
increase in risk varies depending on the patient, with factors including severity and 
duration of the inflammatory process, efficacy of chosen therapy and management of the 
inflammation, and variability among patients [19]. The difference between CRC and 
CAC is simple, CRC tumors, by definition, do not arise in the context of preceding 
inflammation, whereas CAC is always preceded by a chronic inflammatory state [20]. 
For example, a single injection of the carcinogen azoxymethane, a common inducer of 
colon cancer, into mouse models with colitis resulted in malignancy whereas wild type 
mice required multiple injections [21]. It has been shown that in CAC, inflammatory and 
oncogenic pathways are intertwined [20]. Clearly, inflammation plays an important role 
in cancer risk and formation. 
 The purpose of this study is to analyze the literature to understand the great 
microbial variation between populations and what constitutes a favorable and an 
unfavorable environment. This will help us understand the impact gut microbes have on  
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chronic inflammatory processes and how specific microbial populations may promote or 
inhibit chronic inflammation. Furthermore, the exact inflammatory mechanisms microbes 
may interact with will be linked with the oncogenic pathways commonly implicated in 
CAC cases. Lastly, treatment and prevention options will be researched to evaluate the 
candidacy of targeting microbial inflammatory pathways.  
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PUBLISHED STUDIES 
Microbial Variation Among Population 
 With over 1000 species of microbes found within a typical gut and about 1013-14 
cells comprising 90% of the DNA found within the human body, it can be daunting to 
characterize the variation found within the microbiome [22].  However, it is crucial to 
understand in the context of IBD and CAC development as certain microorganisms have 
been found to induce pro-inflammatory pathways, through cytokines, including IL-17 and 
IFNγ, and others found to induce suppressive pathways, including IL-10. [23, 24]. For 
example, certain genera elevated in CD and UC patients include Chlamydia, 
Mycobacterium, Candida, and various E. coli species [25]. Conversely, certain species of 
the Firmicultes and Bacteroidetes phyla have been found to be decreased in IBD [26]. 
This indicates there may be certain species that fall within the “bad” and “good” groups 
of bacteria.  
 Multiple attempts at characterizing the human microbiome are currently 
underway, including the metaHIT project and the Human Microbiome project [27]. Both 
share the goal of characterizing what is defined as a healthy microbiome and what 
differences may occur that result in disease. Their focus include the diversity amongst 
different human populations as well as factors that may cause diversity throughout a 
human’s lifespan. One question arises when classifying the microbiome regarding 
whether to focus on classifying taxonomically or functionally. Studies have shown that  
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>1000 phylotypes, or clusters of sequences with as much diversity within the small 
subunit rRNA genes in a single species, can be found within an individual’s gut [28]. The 
most dominating phyla have been found to comprise less than 0.5% of the microbial 
population, resulting in difficulty defining a core set of species found amongst many 
humans. On the other hand, one confirmed study showed 18 females shared greater than 
93% of enzyme functional groups, but few genus phylotypes [29], indicating a core set of 
functional groups exists amongst individuals despite stemming from different species of 
bacteria. Unsurprisingly, many of these shared metabolic pathways involved 
carbohydrate and amino acid metabolic pathways, pathways which are vital for survival 
[29]. Therefore, it becomes much more feasible to classify differences in enzyme and 
function rather than taxonomic classification.  
 Shortly after birth, the human microbiome is colonized by bacteria and remains 
dynamic during the first few years of life. Stability and diversity tend to increase rapidly 
during the first three years, marking this as a crucial period for microbiome development 
[30]. Factors which may have wide bearing affects during this time period include 
antibiotic administration, breastfeeding, and mode of childbirth delivery [31]. The 
implications of each are not well understood, though they are believed to be linked in 
childhood asthma and eczema.  
 A key player in the development, variety, and stabilization of an individual’s 
microbiome is the intestinal environment resulting from the diet. For example,  
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individuals with a high fiber diet from areas of Africa, Venezuela, and Malawi have been 
shown to have gut microbiome dominated by the genus Prevotella, whereas individuals 
with diets rich in protein and saturated fats are found to have guts dominated by species 
of the genus Bacteroides [32]. Interestingly, IBD is more common in these Western diets 
comprised of protein and saturated fats when compared with high fiber diets [33]. An 
additional variation among populations is found when considering the digestion of soy 
products. (S)-equol is a bacterial byproduct from the digestion of soy and is implicated in 
positive outcomes for various disorders, including vasomotor symptoms, osteoporosis, 
prostate cancer, and cardiovascular disease [34]. However, when a Western population is 
fed soy, 25-30% of the population is found to produce (S)-equol, while 50-60% of the 
Chinese, Korean, and Japanese populations tested produced (S)-equol when fed soy [35]. 
This indicates soy may not be as beneficial to different populations while also suggesting 
other compounds may have different effects depending on the population tested. 
Acetaminophen is one example of microbial byproducts altering metabolism. In 
populations with gut microbes which produce p-cresol, substrate competition occurs. P-
cresol competes with sulfonation of acetaminophen, resulting in decreased concentrations 
of acetaminophen sulfate and increased concentrations of acetaminophen glucuronide 
through a different pathway, altering overall efficacy and toxicity [36]. However, the 
populations with which elevated p-cresol is found is not well understood. This finding 
indicates that many compounds when ingested may have differing effects when 
compared between different populations.  
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 Understanding that an individual’s microbiome has effects, both positive and 
negative, on the GI tract, one may ask if it is possible to alter the microbial population. 
Once established, an individual’s gut remains in a steady state, where the dominant 
microbial population resists change and outcompetes exogenous microbe, both beneficial 
and harmful. Perturbation can be defined as the amount of stress required to result in a 
different, stable community within the gut [37]. In a human trial, two courses of 
ciprofloxacin were given over 10 months. By the end of the trial, the microbiota found 
within stool samples for most individuals had been found to return to the original state, 
though the speed, extent of change, and recovery did vary between individuals [38]. With 
one individual in the study, the first treatment resulted in a slow, unstable, microbiome 
recovery while the second treatment resulted in fast and stable recovery, suggesting the 
first treatment may have resulted in antibiotic resistance development. Another individual 
in the same study differed with the first treatment resulting in a quick, stable microbiome 
recovery to original state, but the second treatment resulted in stabilization to a different 
state, suggesting decreased resistance to perturbation. In another study, three individuals 
suffering from dyspepsia were given 1 week metronidazole, clarithromycin, and 
omeprazole treatment, which resulted in a microbiome state shift lasting 4 years with no 
additional antibiotic treatment [39]. Given these findings, it seems perturbation using 
antibiotics varies among individuals. Rather than using antibiotic treatment, additional 
bacteria may be introduced into the system. Phylogenetically similar bacteria have been 
found to promote each other’s survival and not compete with each other [40]. This  
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finding is thought to be due to each group promoting an environment which is mutually 
beneficial. However, in mouse models with relatively homogenous gut microbes, 
susceptibility to colonization by exogenous pathogens or exogenous commensal bacteria 
was found to be higher than mice with more diverse microbiota [41]. This finding 
indicates that a highly diverse microbiota is beneficial in defending against pathogenic 
invaders.  
Key Inflammatory Pathways 
Before studying the effects that microbial misbalance has on the mucosal layers 
and its immunologic defense, it will be useful to understand the key pathways involved. 
Within the gut, the β-catenin is the main pathway involved in epithelial renewal [42]. 
Hyperactive activation of the pathway results in enhanced cell proliferation from the 
crypt and reduces cell shedding [43]. Common mutations which cause CAC include 
mutations in genes encoding APC, a tumor suppressor, and GSK3B, a kinase, which 
controls APC and β-catenin activity [42]. Early mutations in APC are found in over 30% 
of human CRC cases [44]. However, in CAC mouse models, mutations in p53 and k-ras 
are found initially while up-regulatory β-catenin and inhibitory APC mutations are found 
later in tumor development [45]. The question arises, why is β-catenin and APC crucial 
for the initiation of sporadic CRC development, whereas in CAC these mutations occur 
much later? Inflammation may be a cause of up-regulation of the pathway without the 
need for oncogenic alterations. This is supported by the finding that mice lacking IL-10  
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may form colitis and resulting colorectal tumors, which have elevated β-catenin activity 
but lack APC mutations [46]. Additionally, soluble mediators, including prostaglandin E2 
are found to be elevated during colitis induced inflammation [47]. These soluble 
mediators act on the AKT, PI3K, and NF-κB pathways which also enhance β-catenin 
activity in the absence of APC mutations. [48, 49]. These findings indicate that oncogenic 
mutations are not required to promote hyperactive cell proliferation, but inflammation 
may be a driving force as well. Pro-inflammatory immune cells, including neutrophils 
and activated macrophages can also have inflammatory and oncogenic effects through the 
production of reactive nitrogen intermediates (RNIs) and reactive oxygen species (ROS) 
[50]. Specifically in regards with ROS, oxidative inactivation of mismatch repair and 
other DNA repair mechanisms have been linked to CAC development [51].  
 10 
Figure 1: The role of WNT signaling in intestinal epithelial renewal. Active WNT 
promotes activated β-catenin accumulation, which subsequently translocates to the 
nucleus and activates transcription of proliferative proteins [132].  
A commonality between guts afflicted by IBD and guts afflicted by CAC is 
elevation of NF-κB activity, a transcription factor regulating inflammatory pathways 
[52]. Patients suffering CAC have increased NF-κB activity within immune cells as well 
as within malignant epithelial cells [53]. Many IBD treatments act by targeting NF-κB 
either directly or indirectly, resulting in symptom improvement, with one  
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study utilizing antisense phosphorothioate oligonucleotides which bind and inhibit NF-
κB activity [54]. In a different study, mouse CAC models lacking NF-κB expression 
within epithelial cells were treated with pro-inflammatory compound DSS, resulting in 
increased inflammation but fewer numbers of tumors [55]. This is thought to be due to 
NF-κB control of anti-apoptotic gene expression and in these mice, premalignant cells 
were able to produce an apoptotic response in the absence of NF-κB activity. In another 
study, mouse CAC models with myeloid cells lacking NF-κB were shown to have 
reduced tumor number and size, thought to be due to pro-inflammatory cytokine 
production being crucial to tumor initiation and growth which were lacking in these mice 
[56]. Clinically, TNF and IL-1 are two of these pro-inflammatory and tumor-promoting 
cytokines successfully being targeted for the treatment of IBD [57]. However, in the case 
of untreated and chronic inflammation, pathways between pro-inflammatory and pro-
tumorigenic pathways will interweave.  
Figure 2. Summary of NF-κB downstream effectors. NF-κB is known to promote key 
pathways which result in neoplastic characteristics of epithelial cells [133].  
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Genetically, efforts have been made to detail the early events of CAC 
development. Initially, p53 mutations were found early in inflamed tissues [58]. 
Additionally, epigenetics plays a role, specifically with methylation of DNA and histones 
encoding APC, INK4a, and MLH were found in CAC. [59]. DNA methyltransferases 
were also found to be upregulated by inflammatory cytokines IL-6 and IL-22 [60]. 
Interestingly, miRNA silencing has also been shown to be activated by chronic 
inflammation and seen in CAC [61]. STAT3 and NF-κB are crucial transcription factors 
implicated in their role in CAC development. Removal of STAT3 or NF-κB expression in 
intestinal epithelial cells results in reduced expression of anti-apoptotic genes, including 
Bcl-2 and Bcl-xL, indicating their upregulation through inflammatory processes is crucial 
for hyperplastic cell survival. [62]. STAT3 mediated activation through cytokines is not 
only an important step in regulating these anti-apoptotic genes, but also cell cycle 
regulators, growth factor receptors, and resistance factors [63]. Therefore, it becomes 
important to understand the activators of STAT3 and its downstream effects. IL-6 is a 
potent activator of STAT3 which activates PI3K through JAK/STAT and Ras through 
GPCRs, each found on both malignant and normal epithelial cells [64]. One of the many 
downstream effects of Ras includes secretion of IL-8 which will result in increased 
immune cell infiltration, angiogenesis, and increased tumor size [65]. Immunologically, 
IL-6 has been shown to increase survival of T cells, promote differentiation to Th-17 
cells, and suppress Treg cells within the gut [66]. Th-17 cell differentiation results in 
reduced mucin production as well as cadherin expression, crucial in tumorigenesis as  
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well as mucosal exposure to inflammatory cytokines and pro-inflammatory microbial 
byproducts [67]. With these findings in mind it is no surprise to see that inhibition of IL-6 
has been shown to be effective in treating IBD in both mouse models and human trials 
[68, 69]. In the context of CAC, IL-6 is elevated systemically as well as locally within the 
gut, promoting cell proliferation [70]. In CAC, T-cell transcription factor NFATC2 and 
myeloid cell transcription NF-κB are responsible for the production of IL-6 [71]. This 
finding illustrates the interplay between NF-κB and STAT3 pathways. Interesting to note, 
deletion of STAT3 from neutrophils and activated macrophages within mice results in 
colitis development, likely due to an upregulated Th1 response [72]. An additional crucial 
cytokine for the development of chronic inflammation is IL-23. Polymorphisms in its 
promoter have been associated with increases and decreases in risk for chronic 
inflammation [73]. IL-23 is normally found within the colon and distal ileus, but in CAC, 
IL-23 is severely increased throughout the colon [74]. Suppression of IL23 and it receptor 
has been shown to reduce tumor size and number, as well as reduce concentrations of 
inflammatory cytokines in CAC mouse models. With chronically elevated pro-
inflammatory cytokines and growth factors, premalignant epithelial cells will increase in 
proliferation and reduce in protective apoptosis. Once malignancy has been established, 
solid tumors are then able to continue upregulating these pro-inflammatory cytokines, 
propelling tumor progression and eventual metastasis [14].  These studies have shown 
that oncogenic mutations are not required for the initiation of tumor development. Prior 
chronic inflammatory states are sufficient in promoting hyperplasia, which then may lead  
 14 
to oncogenic development if left untreated.  
Figure 3. Summary of STAT3 actions. Overactive STAT3 signaling may result in 
transcription of proteins which cause cell survival and proliferation [134].  
Microbiota: The Link Between Inflammation and Tumorigenesis 
Establishing multiple pathways of chronic inflammation begs the question of how 
the microbiome plays a role in tumor development. For example, one study showed IL-10 
knockout mice are more likely to develop colitis under normal conditions, but when  
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grown in pathogen free conditions the colitis was less likely and less severe [75]. In a 
follow up study, an uncontrolled Th1 response resulted in worsening colitis and 
subsequent carcinoma formation in the same knockout mice [76]. In a similar study, gut 
sterilization in IL-10 knockout mice resulted in reduced colitis and CAC tumors, but 
chronic inflammatory processes were sufficient in promoting tumor initiation [77]. The 
study indicated chronic inflammation in IBD and colitis were sufficient in producing a 
genotoxic result. In the context of chronic inflammatory processes of the gut, many 
disruptions of the epithelial-mucus barrier may arise which provides an opportunity for 
bacterial infection to promote tumorigenesis [78]. Important to note, similar disruptions 
may be caused by colitogenic chemicals and infectious agents which cause colonic 
injury, including both DSS and enterotoxic bacteria, Bacteroides fragilis [79]. This 
barrier disruption will result in increased contact between the microbiome and the 
underlying epithelial and immune cells. Disruptions of the mucus layer or epithelial 
junctions is one example which increases risk of inflammation as was seen in a study 
done in mouse models in which a crucial component of the mucus layer, Muc2, was 
inactivated. Initially, the result was intestinal inflammation which progressed into CAC 
in the absence of additional carcinogenic factors [80]. Expectedly, when repeated in  
APC-/- mice, the result was increased number and size of CAC tumors through supposed 
inflammation and overactive Wnt signaling [81]. Current IBD therapies are successful in 
treating symptoms, but unsuccessful in ensuring a full recovery of the mucosal barrier 
[82]. This may be the cause of IBD flare ups seen in patients, where a localized area of  
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the intestine is not adequately healed and protected, resulting in episodes of increased 
inflammation. This conjecture has been confirmed by endomicroscopy, which identified 
local barrier dysfunction within patients suffering IBD relapse [83]. With prolonged 
injury, induction of wound healing pathways can result in stem cell proliferation and 
expansion to repair the damaged mucosa. If these active cells contain oncogenic 
mutations, repetitive injury and proliferation may result in tumor formation [84]. 
Additionally, a pro-inflammatory Th-17 response will result in reduced mucin production 
and cadherin expression, further weakening the mucosal barrier [85]. In the case of 
established tumor growth, mutations in p120 catenin, a core component of E-cadherin 
stability, will result in reduced epithelial junction strength [86]. One strain in particular, 
Fusobacteria, has been shown to bind e-cadherin displayed on cancerous cells through 
FadA adhesion protein, resulting in growth stimulation in addition to infiltration of the 
bacterium to neighboring tissue, eliciting a tumorigenic immune response [86]. With a 
damaged mucosal barrier, the epithelial and immune cells are increasingly exposed to the 
environment rich in microbes and their byproducts. In this case, commensal bacteria are 
capable of eliciting an overactive immune response. Toll-like receptors (TLRs) are key 
mediators in activation of the immune response, with the ability to recognize exogenous 
substrates and subsequently activate pro-inflammatory downstream pathways discussed 
earlier [88]. For example, a deficiency in TLR-4 signaling, the receptor responsible for 
binding microbial antigen, lipopolysaccharide (LPS), has been shown to reduce the risk 
of CAC [89]. Likewise, overexpression of TLR4 will result in an overactive, hyper- 
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proliferative response and subsequent neoplasia [90]. Mouse models deficient in TLR 
adaptor protein, MyD88, also exhibit reduced intestinal tumor progression as well as 
reduced inflammation overall [91]. In humans, elevated TLR4 and MyD88 expression 
correlate with a poorer CAC prognosis [92]. The result of increased microbial recognition 
is increased cytokine production, activation of fibroblast infiltration, and further support 
of tumor growth [93]. Damage to the mucosal barrier within the gut establishes the 
opportunity for normally commensal bacteria to become harmful, by exposure to 
microbial antigen to the underlying immune cells and resulting inflammatory response.  
Figure 4. Effects of mucosal damage to underlying epithelium. In the context of sustained 
epithelial damage, commensal microbes may activate an inflammatory immune response 
[135]. 
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With the underlying chronic inflammation established and the mucosal barrier 
exposed to increasing amounts of pro-inflammatory products, the cycle self-perpetuates 
until malignancy formation if left untreated. In the case of chronic inflammation, the 
underlying epithelium is exposed to microbial antigens and byproducts, resulting in 
further inflammation and oncogenic modifications [94]. The commensal microbiome will 
induce cytokines, including IL-23, IL-6, IL-22, and IL-17, resulting in signaling 
promoting barrier weakness and adenoma formation [95]. This is shown in HB-EGF 
transgenic mice, which have increased risk of polyp formation. Failure of the intestinal 
barrier in these mice allows microbial induction of neutrophil accumulation, subsequent 
inflammation, and ultimately tumor development [96]. Interestingly, treatment with 
antibiotics reduced polyp formation while reintroduction of stool samples from pre-
treatment resulted in continued polyp formation, indicating bacteria played a role in 
tumor development. Additionally, when the colonic wall is injured, IL-18 has been 
shown to downregulate IL-22BP, resulting in an increase of IL-22 signaling and 
following tumor promotion. [97]. Likewise, inhibition of IL-22 resulted in reduction of 
inflammation as well as reduction in tumor burden in this microbial CAC mouse model 
[98]. Through multiple pathways, microbes enhance the pro-inflammatory response, 
resulting in the activation of multiple proliferative pathways.  
One question which arises is if pro-inflammatory microbes are a requirement for 
IBD which then accelerates disease progression or if specific strains of microbes are  
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found to be elevated in cases of IBD which promote CAC. Multiple strains of bacteria 
have been shown to directly exacerbate CAC tumor development, including strains of E. 
coli, Streptococcus bovis, H. pylori, and Bacteroides fragilis [99]. These strains have 
been shown to attach to epithelial layers of colonic tissue and induce inflammation, 
proliferation, and resulting hyperplasia [100]. Additionally, toxins may be produced 
which directly disrupt barrier integrity, damage cells, and ultimately promote 
inflammatory processes. Specifically, in the case of E. coli, there has been a direct link 
between attachment and tumor infiltration with poor prognosis in humans [101]. It is 
believed E. coli achieves this by attachment to colonic epithelial cells and promotion of 
hyperplasia and inflammation. It has also been shown that normally commensal bacteria 
may translocate and subsequently trigger an immune response during intestinal wall 
injury. [102]. One example of this is a study which demonstrated commensal E. coli 
upregulating IL-17c expression in CAC mouse models, resulting in apoptotic suppression 
through induction of Bcl-xl and recruitment of lymphocytes, ultimately promoting 
tumorigenesis [103]. An increase in IL-6 producing lymphocytes and increased epithelial 
proliferation has been seen in CAC mouse models with inflammosomal protein removal 
[104]. This is thought to be due to selection of pro-inflammatory microbes which induce 
upregulation of epithelial CCL5. In the same study, inhibition of IL-6 resulted in reduced 
inflammation and reduced tumorigenic burden by blocking the effects of the selected pro-
inflammatory microbes. In a different study, anti-inflammatory microbes were shown to 
induce IL-10 secretion in response to intestinal wall injury, resulting in protection from  
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tumor formation in mouse models [105]. These two studies illustrate that imbalance 
between pro-inflammatory and anti-inflammatory microbes can result in unfavorable, 
proliferative states. Virulence factors have also been found to exert tumorigenic effects 
by damaging DNA and damaging mucosal integrity. One example of this is a study 
researching strains of E. coli which express polyketide synthase, producing a genotoxic 
compound, which when induced in IL-10-/- mouse models, greatly increased number of 
colonic tumors [106]. Bacteroides fragilis has also been shown to produce a toxin with a 
number of tumorigenic actions, including e-cadherin cleavage, upregulation of β-catenin 
activity, Th-17 cell differentiation, and upregulation of NF-κB signaling [107]. The latter 
of which is clinically relevant as increased Th17 cell infiltration correlates with further 
tumor progression and poorer colorectal cancer prognosis [108]. Finally, strains of 
fusobacterium have been shown to be implicated in IBD and to be enriched in CACs. 
[109]. There are many examples of specific strains of bacteria enhancing tumorigenesis 
by disrupting epithelial integrity, activating inflammatory processes, promoting 
oncogenic mutations, and ultimately resulting in a hyper-proliferative states.  
Prevention and Treatment 
Understanding the effects of chronic inflammation promoted by microbial 
interaction with the enteric immune system, it is interesting to consider preventative 
measures as well as treatment options to reduce the risk of hyperplasia and malignancy 
formation. Multiple options may be considered, including treatment pathways targeting  
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microbes and microbial antigen as well as pathways targeting chronic inflammatory 
processes. Additionally, prevention of a pro-inflammatory state must be considered due 
the long-term inflammation increasing risk of CAC development [15].  
Antibiotic treatment is an obvious choice in depletion of a pro-inflammatory 
microbe population. Antibiotic treatment has been proven to improve colitis in both 
humans and mice who contain a complex microbiome [110]. In this study, IL-10-/- mouse 
models infected with Helicobacter resulted in CAC development unless treatment with 
antibiotics, improving both IBD and CAC states. In a different colon adenoma mouse 
model, antibiotic reduction of commensal bacteria was found to reduce inflammation and 
tumor burden significantly [111]. In human patients with MALT lymphoma, reduction of 
H. pylori population through antibiotic treatment was found to significantly improve 
outcomes, and in uncommon circumstances, result in cancer remission. [112]. Meta-
analysis of multiple antibiotic treatment trials in human IBD patients has shown that 
broad spectrum antibiotics were successful in improving disease outcomes [113]. 
Reduction of commensal bacteria using antibiotics has been shown to normalize colon 
morphology, while also providing increased mucin production and reduction of 
inflammatory cell infiltration [114]. Overall, antibiotic treatment appears to be a viable 
option for both treatment of chronic inflammation caused by microbes as well as 
reduction of tumor growth [114]. However, problems arise when considering 
consequences of abundant antibiotic usage, including resistance formation as well as  
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reduction in beneficial, anti-inflammatory microbes.  
An additional treatment option may be to target inflammatory pathways 
themselves. One group has shown NSAIDs and specific cyclooxygenase inhibitors have 
been successful in reducing the incidence and severity of CRC as well as reduction of 
tumor growth [115]. Aspirin and NSAIDs have been shown to reduce CRC incidence by 
up to 50%, and has been shown that the inhibition of COX-2 resulted in reduced 
inflammation and a reduction in tumor cell proliferation and migration [116]. As 
previously mentioned, ROSs and RNIs induced by pro-inflammatory microbes are 
pathways leading to increased inflammation and subsequent proliferation. Expectedly, 
inhibition of ROS production has been shown to result in a reduction of IBD symptoms 
in humans [117]. Additionally, activation induced cytidine deaminase is an enzyme found 
to be overexpressed in many cancers and leads to genetic instability [118]. Targeting this 
enzyme, both pharmacologically and genetically, has been shown to disrupt colorectal 
tumorigenesis [119]. Lastly, inhibition of inducible NO synthase, responsible for the 
production of RNIs, has been shown to be an effective method of reducing DNA damage 
[120]. As discussed earlier, premalignant cells can be induced to produce ROS and RNI 
by pro-inflammatory cytokines. Inhibition of chronic inflammatory processes seem to be 
viable in ameliorating IBD symptoms and CAC development.  
An emerging treatment option involves replacement of undesirable, pro-
inflammatory bacteria with beneficial bacteria. Because species of Fusobacterium have  
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been implicated in IBD and enriched in CRC patients, depletion of these microbes 
followed by replacement with anti-inflammatory bacteria may be beneficial [121].  A 
distinction can be made between different treatment options. Prebiotics can be define as 
indigestible foods which selective promote growth of a desired microbe, while probiotics 
can be defined as an organism which will result in a health benefit when ingested [122]. 
Both forms have been increasingly been used as treatments in recent years. [123]. One 
cross-sectional study studied the association between dietary fiber ingestion and the 
presence of bacteria producing butyrate within stool samples compared between a group 
with colorectal cancer and a group without colorectal cancer [124]. Their findings 
showed diets low in fiber did impact the number of butyrate producing bacteria and short 
chain fatty acid synthesis. Another studied showed a diet high in fiber increased 
methanogenesis in the gut, which resulted in a reduction of hydrogen producing bacteria 
[123]. The researchers believed this to be impactful because excess colonic hydrogen 
resulted in decreased NAD regeneration. Ultimately, fiber rich diets have been proven to 
be beneficial in reducing inflammatory bacteria and promoting growth of anti-
inflammatory microbes, including Faecalibacterium prausnitzii [125]. Examples of 
probiotics currently in use include Lactobacillus and Bifidobacterium, the former of 
which has been shown to reduce intestinal inflammation and CAC in animal models 
[126]. However, both have been shown to increase detoxification of toxic metabolites and 
carcinogens within the colon, promote anti-tumorigenic immune responses, and produce 
compounds which are anti-oncogenic and anti-mutagenic by interacting directly with  
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proliferative cells, resulting in growth inhibition [127]. Infection with LTA deficient 
Lactobacillus acidophilus has also been shown to reduce colitis and cancer development 
in mice [128]. Both prebiotic and probiotic treatment appears to be beneficial in the 
treatment of IBD and prevention of CAC. One final form of bacteriotherapy which shows 
promise has been fecal transplantation. The treatment includes the introduction of fecal 
homogenate from a healthy donor into the cecum of the patient. In otherwise untreatable 
cases of IBD, fecal transplantation has been shown to have positive outcomes in humans 
[129]. In another case, patients suffering from C. diff induced colitis, or CDAD, were 
found to contain stool dominated by Veillonella and Streptococcus species. When 
transplanted with donor stool dominated by species of Bacteroides, the disease state was 
resolved and Bacteroides were found to be the dominant species 1 month later [130]. In a 
study evaluating the efficacy of fecal transplantation, 92% of 317 cases were found to 
have disease clearance [131]. The importance of replacing pro-inflammatory microbes 
with anti-inflammatory microbes to treat chronic inflammatory disease is crucial, likely 
due to an established microbial population preventing further reinfection of the gut.    
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DISCUSSION 
 The interplay between the human microbiome and the gastrointestinal system is 
complex. Interactions between microbes and the host immune system lies in a balance 
between pro-inflammatory and anti-inflammatory states. Researching these 
immunological interactions is crucial in understanding the chronic inflammatory 
dysfunctions which affect many today. Difficulty arises when attempting to classify a 
beneficial microbial ecosystem compared to a harmful ecosystem. Rather than classifying 
taxonomically, classifying by role in disease progression is a more feasible task. Many 
strains have been found to affect the intestinal ecosystem in negative ways while others 
have been found to promote ecological health within the gut. Groups have found diet 
plays a role in determining the overall health of an individual’s microbial ecosystem. 
Specifically, diets rich in fiber have been shown to be advantageous while diets rich in 
saturated fats have been disadvantageous. However, due to the settlement of a dominating 
microbiome shortly after birth, it becomes difficult to assess which diet options are 
beneficial to one population or another. Regardless, once a chronic inflammatory disease 
process begins, it is crucial to combat before progression continues. 
 Previously stated, oncogenic mutations are not a requirement for colorectal cancer 
initiation. Overactive inflammatory pathways alone are sufficient in promoting 
hyperplasia, which may subsequently result in oncogenic mutations, further promoting 
tumorigenesis. Pathways involving NF-κB and STAT3 result in increased cytokine  
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production, promoting growth, proliferation, lymphocytic infiltration, and an anti-
apoptotic state. Through chronic activation of these inflammatory pathways, the risk of 
tumorigenesis occurring rises. 
 The microbiome itself can play a role in the chronic inflammatory state resulting 
in tumor development. Certain strains of bacteria have been known to produce 
inflammatory states by interacting with the immune system. Once damage to the mucosal 
wall is established, otherwise commensal bacteria become exposed to the underlying 
tissue. This exacerbates disease progression, as continued exposure to microbial antigen 
results in a chronic inflammatory state.  
 Multiple treatment options are currently being used and researched for the use of 
treatment and prevention of chronic inflammation. NSAIDs have been helpful in 
treatment of IBD patients through the inhibition of cyclooxygenase pathways. The 
resulting inhibition may ameliorate symptoms, but if mucosal wall integrity has been 
compromised, IBD flare-ups have been shown to return to the localized damage. 
Additionally, NSAIDs run the consequence of promoting gastric ulcers. Another 
treatment option involves antibiotic treatment. Previously stated, the microbiome is 
susceptible to perturbation. Antibiotics may be useful in exterminating harmful bacteria 
at the cost of reducing beneficial bacteria populations as well. Overuse of antibiotics is 
also a detriment as resistance is likely to form. One treatment option involves 
transplanting beneficial bacteria from a known host to a donor suffering from chronic  
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inflammation. The success rates with this method are good, especially if the exogenous 
microbes can colonize the intestine. Treatment with antibiotics beforehand may help 
perturb the pre-existing microbial population to allow for colonization by donor bacteria. 
Lastly, probiotic and prebiotic digestion has been gaining in popularity in recent years. 
With probiotics claiming improved gastrointestinal health with known strains of bacteria 
which deter inflammation, skeptics believe this method of prevention has challenges. 
First, the exogenous microbes must pass through the acidic environment of the stomach, 
thereby eliminating a number of the introduced microbes. Secondly, in a healthy, 
thriving, and established microbial population, exogenous microbes, both beneficial and 
harmful, may find difficulty with colonization due to competition for nutrition. The 
previously described fecal transplantation benefits in avoiding the acidic digestive tract. 
On the other hand, prebiotics promote a gastrointestinal environment which will favor 
beneficial bacteria. As previously mentioned, fiber rich diets will promote the growth of 
anti-inflammatory bacteria, while diets rich in saturated fats may promote the growth of 
pro-inflammatory bacteria. The distinction between prebiotics and probiotics lies within 
prevention and treatment. Prevention is preferred over symptom treatment as mucosal 
wall injury will result in susceptibility to further damage. Additionally, treatment with 
antibiotics and anti-inflammatory agents have secondary effects. Diet, on the other hand, 
can prevent the initiation of chronic inflammatory processes. However, in some cases 
IBD and CAC occur in cases where diet is not the primary promoter of the disease. 
Further research must be established in those cases to treat patients before tumorigenesis 
can establish.   
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